1st Division of Gastroenterology, A.M. & A. Migliavacca Center for Liver Disease, Fondazione IRCCS Ca' Granda Maggiore Hospital, Università degli Studi di Milano, Via F. Sforza 35, Milan 20122, Italy.
Clin Liver Dis. 2013 Aug;17(3):375-97. doi: 10.1016/j.cld.2013.05.002. Epub 2013 Jul 3.
The hepatitis B virus (HBV) plays a dominant role in the 749,000 new cases and 692,000 deaths related to hepatocellular carcinoma (HCC) that are estimated to occur each year worldwide. Chronic infection with HBV is responsible for 60% of HCCs in Asia and Africa and at least 20% of the tumors in Europe, Japan, and the United States. This article discusses the pathogenic role of HBV and the risk of HCC. Tumors almost invariably develop in the context of chronic hepatitis or cirrhosis, which makes early diagnosis the only practical approach to improve prognosis. The treatment options are also discussed.
乙型肝炎病毒（HBV）在全球每年估计发生的 74.9 万例新病例和 69.2 万例与肝细胞癌（HCC）相关的死亡中起主导作用。HBV 的慢性感染占亚洲和非洲 HCC 的 60%，欧洲、日本和美国的肿瘤至少占 20%。本文讨论了 HBV 的致病作用和 HCC 的风险。肿瘤几乎总是在慢性肝炎或肝硬化的背景下发展，这使得早期诊断是改善预后的唯一实用方法。还讨论了治疗选择。
